{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:35:53Z","timestamp":1791610553137,"version":"4.3.4"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    The human immunodeficiency virus (HIV) persists in latently infected CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV\/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine\/tenofovir disoproxil fumarate\/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1294966","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T08:12:46Z","timestamp":1698307966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Current drugs for HIV-1: from challenges to potential in HIV\/AIDS"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.3390\/molecules27123936","article-title":"The Glu143 residue might play a significant role in T20 peptide binding to HIV-1 receptor gp41: an in silico study","volume":"27","author":"Alaofi","year":"2022","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"104975","DOI":"10.1016\/j.antiviral.2020.104975","article-title":"Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca(2+) homeostasis in skeletal muscles","volume":"187","author":"Alomar","year":"2021","journal-title":"Antivir. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/14787210.2017.1323634","article-title":"Atazanavir sulfate + cobicistat for the treatment of HIV infection","volume":"15","author":"Antunes","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/21505594.2020.1760443","article-title":"Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages","volume":"11","author":"Aquaro","year":"2020","journal-title":"Virulence"},{"key":"B5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","article-title":"Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile","volume":"65","author":"Arvieux","year":"2005","journal-title":"medications"},{"key":"B6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/COH.0000000000000534","article-title":"HIV subtype diversity worldwide","volume":"14","author":"Bbosa","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/cid\/ciaa1026","article-title":"Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV)","volume":"72","author":"Bekker","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/COH.0000000000000473","article-title":"Ibalizumab","volume":"13","author":"Bettiker","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: a review in multidrug-resistant HIV-1 infection","volume":"80","author":"Blair","year":"2020","journal-title":"medications"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.coviro.2021.09.009","article-title":"Drug resistance mutations in HIV: new bioinformatics approaches and challenges","volume":"51","author":"Blassel","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/14656566.8.7.957","article-title":"Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?","volume":"8","author":"Boyd","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1874467211003020091","article-title":"New prospects for nelfinavir in non-HIV-related diseases","volume":"3","author":"Bruning","year":"2010","journal-title":"Curr. Mol. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/s2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"B15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00430-022-00732-x","article-title":"HIV-1 restriction by SERINC5","volume":"212","author":"Cano-Ortiz","year":"2023","journal-title":"Med. Microbiol. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1389203723666220610120927","article-title":"Peptide triazole inhibitors of HIV-1: hijackers of env metastability","volume":"24","author":"Carter","year":"2023","journal-title":"Curr. Protein Pept. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17460441.2022.2117296","article-title":"The discovery and development of RNA-based therapies for treatment of HIV-1 infection","volume":"18","author":"Chen","year":"2023","journal-title":"Expert Opin. Medicat. Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14656566.2022.2029409","article-title":"An up-to-date evaluation of dolutegravir\/abacavir\/lamivudine for the treatment of HIV","volume":"23","author":"Christensen","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0000000000000597","article-title":"Long-acting injectable cabotegravir for the prevention of HIV infection","volume":"15","author":"Clement","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/QAD.0000000000002886","article-title":"Fixed-dose darunavir\/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns","volume":"35","author":"Dash","year":"2021","journal-title":"AIDS"},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"medications"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40265-018-0934-2","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"medications"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/00042560-199805010-00007","article-title":"Foscarnet decreases HIV-1 plasma load","volume":"18","author":"Devianne-Garrigue","year":"1998","journal-title":"J. Acquir Immune Defic. Syndr. Hum. Retrovirol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pbj.2017.06.002","article-title":"The path towards an HIV vaccine","volume":"45","author":"Dispinseri","year":"2022","journal-title":"New Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/HIV.S157855","article-title":"Dolutegravir\/rilpivirine for the treatment of HIV-1 infection","volume":"10","author":"Dowers","year":"2018","journal-title":"HIV AIDS (Auckl)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/medicina59061041","article-title":"Highlights on the development, related patents, and prospects of lenacapavir: the first-in-class HIV-1 capsid inhibitor for the treatment of multi-drug-resistant HIV-1 infection","volume":"59","author":"Dzinamarira","year":"2023","journal-title":"Med. Kaunas."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/jac\/dkx108","article-title":"Once-daily atazanavir\/cobicistat and darunavir\/cobicistat exposure over 72\u2009h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge","volume":"72","author":"Elliot","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"198040","DOI":"10.1016\/j.virusres.2020.198040","article-title":"Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5\u039432 on viral diseases","volume":"286","author":"Ellwanger","year":"2020","journal-title":"Virus Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/QAI.0b013e3182653c1f","article-title":"Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles","volume":"61","author":"Endsley","year":"2012","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1021\/acs.biochem.1c00157","article-title":"Long-acting cabotegravir for HIV\/AIDS prophylaxis","volume":"60","author":"Engelman","year":"2021","journal-title":"Biochemistry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1348-0421.12769","article-title":"Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients","volume":"64","author":"Faridi","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.7326\/0003-4819-124-7-199604010-00006","article-title":"Immunopathogenic mechanisms of HIV infection","volume":"124","author":"Fauci","year":"1996","journal-title":"Ann. Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2105\/AJPH.2018.304757","article-title":"HIV preexposure prophylaxis","volume":"108","author":"Fernando","year":"2018","journal-title":"Am. J. Public Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/acsinfecdis.9b00285","article-title":"Enfuvirtide-protoporphyrin IX dual-loaded liposomes: in vitro evidence of synergy against HIV-1 entry into cells","volume":"6","author":"Figueira","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1097\/00002030-200109070-00013","article-title":"The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial","volume":"15","author":"Fisher","year":"2001","journal-title":"AIDS"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105311","DOI":"10.1016\/j.antiviral.2022.105311","article-title":"HIV protease inhibitors Nelfinavir and Lopinavir\/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect","volume":"202","author":"Foo","year":"2022","journal-title":"Antivir. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","article-title":"HIV-1: fifteen proteins and an RNA","volume":"67","author":"Frankel","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4067\/S0034-98872016000700016","article-title":"Cushing syndrome in a HIV patient using inhaled steroids. Report of one case","volume":"144","author":"Frias","year":"2016","journal-title":"Rev. Med. Chil."},{"key":"B44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2174\/1570162X14666161021102728","article-title":"Atazanavir plus cobicistat: week 48 and week 144 subgroup analyses of a phase 3, randomized, double-blind, active-controlled trial","volume":"15","author":"Gallant","year":"2017","journal-title":"Curr. HIV Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1021\/acs.jmedchem.2c01732","article-title":"Potent long-acting inhibitors targeting the HIV-1 capsid based on a versatile quinazolin-4-one scaffold","volume":"66","author":"Gillis","year":"2023","journal-title":"J. Med. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/QAI.0b013e3181ec2a68","article-title":"The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals","volume":"55","author":"Gordon","year":"2010","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults","volume":"384","author":"Gray","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Group","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/phar.2605","article-title":"Therapeutic review of cabotegravir\/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic","volume":"41","author":"Howe","year":"2021","journal-title":"Pharmacotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"186","author":"Hsu","year":"2023","journal-title":"Cell."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1309","article-title":"Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for ainuovirine, lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects","author":"Huang","year":"2023","journal-title":"Clin. Pharmacol. Medicat. Dev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"86","author":"Huang","year":"2021","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jviromet.2012.10.018","article-title":"Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing","volume":"187","author":"Ji","year":"2013","journal-title":"J. Virol. Methods"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1017\/erm.2013.15","article-title":"Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors","volume":"15","author":"Jurado","year":"2013","journal-title":"Expert Rev. Mol. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e00594","DOI":"10.14309\/crj.0000000000000594","article-title":"Reactivation of hepatitis B after ibalizumab therapy for multidrug-resistant human immunodeficiency virus","volume":"8","author":"Kaplan","year":"2021","journal-title":"ACG Case Rep. J."},{"key":"B122","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00003088-200645070-00003","article-title":"Tipranavir","volume":"45","author":"King","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e016310","DOI":"10.1161\/JAHA.120.016310","article-title":"Association between atazanavir-induced hyperbilirubinemia and cardiovascular disease in patients infected with HIV","volume":"9","author":"Li","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"104177","DOI":"10.1016\/j.ebiom.2022.104177","article-title":"HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein","volume":"82","author":"Liu","year":"2022","journal-title":"EBioMedicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1871526517666170505122800","article-title":"HAART in HIV\/AIDS treatments: future trends","volume":"18","author":"Lu","year":"2018","journal-title":"Infect. Disord. Medicat. Targets"},{"key":"B62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12879-020-4785-6","article-title":"HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study","volume":"20","author":"Lyu","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/QAD.0000000000002902","article-title":"Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age","volume":"35","author":"MacBrayne","year":"2021","journal-title":"AIDS"},{"key":"B64","doi-asserted-by":"publisher","first-page":"634386","DOI":"10.3389\/fimmu.2021.634386","article-title":"Interactions of HIV and antiretroviral therapy with neutrophils and platelets","volume":"12","author":"Madzime","year":"2021","journal-title":"Front. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/v2040880","article-title":"HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate","volume":"2","author":"Maga","year":"2010","journal-title":"Viruses"},{"key":"B66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/sextrans-2020-054714","article-title":"Single-tablet regimen of emtricitabine\/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims","volume":"97","author":"Malinverni","year":"2021","journal-title":"Sex. Transm. Infect."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/jac\/dkab196","article-title":"HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir","volume":"76","author":"Martin","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1086\/314949","article-title":"A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease","volume":"180","author":"Martin","year":"1999","journal-title":"J. Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/AID.2021.0096","article-title":"A randomized, open-label, crossover phase 1 safety and pharmacokinetic study of oral maraviroc and maraviroc 1% gel (the CHARM-03 study)","volume":"38","author":"McGowan","year":"2022","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/14656566.2021.1902504","article-title":"Evaluating the combination of emtricitabine\/tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults","volume":"22","author":"Mesplede","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00126334-200108150-00005","article-title":"Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408","volume":"27","author":"Miller","year":"2001","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B73","doi-asserted-by":"publisher","first-page":"105537","DOI":"10.1016\/j.ejps.2020.105537","article-title":"Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach","volume":"155","author":"Mirza","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/qad.0000000000002857","article-title":"Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV","volume":"35","author":"Momper","year":"2021","journal-title":"Aids"},{"key":"B74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/QAI.0000000000002856","article-title":"Pharmacokinetics of atazanavir boosted with cobicistat in pregnant and postpartum women with HIV","volume":"89","author":"Momper","year":"2022","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B75","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2174\/1570162X19666210908115231","article-title":"Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond","volume":"19","author":"Monteiro","year":"2021","journal-title":"Curr. HIV Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1574884714666191111125348","article-title":"Tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis","volume":"15","author":"Moorthy","year":"2020","journal-title":"Curr. Clin. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1473-3099(23)00075-0","article-title":"Lenacapavir: a new treatment of resistant HIV-1 infections","volume":"23","author":"Mushtaq","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/HIV.S56158","article-title":"Profile of once-daily darunavir\/cobicistat fixed-dose combination for the treatment of HIV\/AIDS","volume":"8","author":"Navarro","year":"2016","journal-title":"HIV AIDS (Auckl)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","article-title":"Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China","volume":"10","author":"Nie","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"key":"B81","doi-asserted-by":"publisher","first-page":"12149","DOI":"10.3390\/ijms232012149","article-title":"Discovery of novel HIV protease inhibitors using modern computational techniques","volume":"23","author":"Okafor","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1345\/aph.1R468","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment","volume":"46","author":"Olin","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"","journal-title":"Lancet HIV"},{"key":"B85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"medications"},{"key":"B88","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"B90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.virusres.2019.03.014","article-title":"Mechanisms of HIV-1 cell-to-cell transmission and the establishment of the latent reservoir","volume":"265","author":"Pedro","year":"2019","journal-title":"Virus Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/biom12070944","article-title":"Saquinavir: from HIV to COVID-19 and cancer treatment","volume":"12","author":"Pereira","year":"2022","journal-title":"Biomolecules"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.3390\/jcm11174994","article-title":"Use of tenofovir alafenamide\/emtricitabine\/elvitegravir-cobicistat in HIV-naive patients with advanced disease: GENIS study","volume":"11","author":"Perez Stachowski","year":"2022","journal-title":"J. Clin. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"19795","DOI":"10.7448\/IAS.17.4.19795","article-title":"Lipid changes in HIV-patients switching to the coformulated single tablet FTC\/RPV\/TDF (Eviplera\u00ae). Efficacy and safety analysis. GeSida Study 8114","volume":"17","author":"Perez-Hernandez","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/QAI.0000000000002595","article-title":"Switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in adults with HIV and M184V\/I mutation","volume":"86","author":"Perez-Valero","year":"2021","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B95","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-013-0158-4","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen (Stribild\u00ae): a review of its use in the management of HIV-1 infection in adults","volume":"74","author":"Perry","year":"2014","journal-title":"medications"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.2165\/00003495-200565150-00015","article-title":"Nelfinavir: a review of its use in the management of HIV infection","volume":"65","author":"Perry","year":"2005","journal-title":"medications"},{"key":"B97","doi-asserted-by":"publisher","first-page":"13596535231159030","DOI":"10.1177\/13596535231159030","article-title":"Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review","volume":"28","author":"Peters","year":"2023","journal-title":"Antivir. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14760584.2020.1718497","article-title":"Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges","volume":"19","author":"Pitisuttithum","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.2147\/dddt.S63989","article-title":"Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV\/AIDS","volume":"9","author":"Putcharoen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/v14040697","article-title":"Drug resistance mechanism of M46I-Mutation-Induced saquinavir resistance in HIV-1 protease using molecular dynamics simulation and binding energy calculation","volume":"14","author":"Rana","year":"2022","journal-title":"Viruses"},{"key":"B100","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/15284336.2019.1608714","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive patients with HIV-1: subgroup analyses of the phase 3 AMBER study","volume":"20","author":"Rashbaum","year":"2019","journal-title":"HIV Res. Clin. Pract."},{"key":"B101","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.tim.2019.04.003","article-title":"RNA packaging in HIV","volume":"27","author":"Rein","year":"2019","journal-title":"Trends Microbiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","article-title":"Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120","volume":"30","author":"Richard","year":"2023","journal-title":"Cell. Chem. Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e09950","DOI":"10.1016\/j.heliyon.2022.e09950","article-title":"The role of CCR5 in HIV-associated neurocognitive disorders","volume":"8","author":"Riviere-Cazaux","year":"2022","journal-title":"Heliyon"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.3390\/ijms20122984","article-title":"Role of the ubiquitin proteasome system (UPS) in the HIV-1 life cycle","volume":"20","author":"Rojas","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/cells8101245","article-title":"New challenges of HIV-1 infection: how HIV-1 attacks and resides in the central nervous system","volume":"8","author":"Rojas-Celis","year":"2019","journal-title":"Cells"},{"key":"B106","doi-asserted-by":"publisher","first-page":"105916","DOI":"10.1016\/j.ejps.2021.105916","article-title":"Multi-organ targeting of HIV-1 viral reservoirs with etravirine loaded nanostructured lipid carrier: an in-vivo proof of concept","volume":"164","author":"Rojekar","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e0235020","DOI":"10.1128\/JVI.02350-20","article-title":"A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2-neutralizing activity","volume":"95","author":"Rubio","year":"2021","journal-title":"J. Virol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","article-title":"Dolutegravir\/lamivudine single-tablet regimen: a review in HIV-1 infection","volume":"80","author":"Scott","year":"2020","journal-title":"medications"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/138955706776876267","article-title":"Novel anti-viral therapy: drugs that block HIV entry at different target sites","volume":"6","author":"Siegert","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.2147\/DDDT.S147493","article-title":"Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era","volume":"12","author":"Squillace","year":"2018","journal-title":"Medicat. Des. Devel Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hiv.12833","article-title":"The potential role of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV","volume":"21","author":"Stellbrink","year":"2020","journal-title":"HIV Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.lanwpc.2023.100769","article-title":"Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine\/tenofovir disoproxil fumarate for medication of treatment-na\u00efve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96","volume":"36","author":"Su","year":"2023","journal-title":"Lancet Regional Health - West. Pac."},{"key":"B117","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/COH.0000000000000466","article-title":"Dolutegravir-rilpivirine coformulation","volume":"13","author":"Sun","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1021\/acs.molpharmaceut.0c00773","article-title":"Long-acting efavirenz and HIV-1 fusion inhibitor peptide Co-loaded polymer-lipid hybrid nanoparticles: statistical optimization, cellular uptake, and in vivo biodistribution","volume":"17","author":"Surve","year":"2020","journal-title":"Mol. Pharm."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"B120","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11904-019-00480-3","article-title":"Recent advances in the development of integrase inhibitors for HIV treatment","volume":"17","author":"Trivedi","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"B121","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir. Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nature15400","article-title":"SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef","volume":"526","author":"Usami","year":"2015","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coviro.2015.06.001","article-title":"HIV-1 genotypic medication resistance testing: digging deep, reaching wide?","volume":"14","author":"Van Laethem","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e0169422","DOI":"10.1128\/aac.01694-22","article-title":"Antiviral properties of HIV-1 capsid inhibitor GSK878","volume":"67","author":"Wang","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B127","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.phrs.2020.105010","article-title":"CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent","volume":"159","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00044-021-02787-6","article-title":"Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir","volume":"30","author":"Wang","year":"2021","journal-title":"Med. Chem. Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fimmu.2017.00210","article-title":"IFN-\u039b inhibits drug-resistant HIV infection of macrophages","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin. Medicat. Metab. Toxicol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"108315","DOI":"10.1016\/j.jmgm.2022.108315","article-title":"HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics","volume":"117","author":"Wong-Sam","year":"2022","journal-title":"J. Mol. Graph Model."},{"key":"B132","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.2147\/DDDT.S90580","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Medicat. Des. Devel Ther."},{"key":"B134","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1208\/s12249-022-02391-w","article-title":"Enzyme responsive delivery of anti-retroviral peptide via smart hydrogel","volume":"23","author":"Yeruva","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"B135","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/cmdc.202000695","article-title":"Structure, synthesis and inhibition mechanism of nucleoside analogues as HIV-1 reverse transcriptase inhibitors (NRTIs)","volume":"16","author":"Yoshida","year":"2021","journal-title":"ChemMedChem"},{"key":"B136","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/pharmaceutics14020406","article-title":"Physiologically based pharmacokinetic (PBPK) model of gold nanoparticle-based drug delivery system for stavudine biodistribution","volume":"14","author":"Zazo","year":"2022","journal-title":"Pharmaceutics"},{"key":"B137","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1542\/pir.19-12-399a","article-title":"Foscarnet","volume":"19","author":"Zeichner","year":"1998","journal-title":"Pediatr. Rev."},{"key":"B138","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/1535370220901498","article-title":"Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors","volume":"245","author":"Zhang","year":"2020","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","article-title":"Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients","volume":"13","author":"Zhang","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.lfs.2009.07.014","article-title":"Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity","volume":"85","author":"Zhang","year":"2009","journal-title":"Life Sci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virs.2022.01.017","article-title":"Updates on CRISPR-based gene editing in HIV-1\/AIDS therapy","volume":"37","author":"Zhang","year":"2022","journal-title":"Virol. Sin."},{"key":"B142","doi-asserted-by":"publisher","first-page":"46344","DOI":"10.1038\/srep46344","article-title":"Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1294966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T08:12:50Z","timestamp":1698307970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1294966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":139,"alternative-id":["10.3389\/fphar.2023.1294966"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1294966","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1294966"}}